2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Breast Neoplasms
6391
Neoplasms
5364
Prostatic Neoplasms
2966
Carcinoma, Non-Small-Cell Lung
2708
Colorectal Neoplasms
2678
Lung Neoplasms
2267
Multiple Myeloma
1663
Lymphoma
1600
Neoplasm Metastasis
1551
Leukemia, Myeloid, Acute
1539
Melanoma
1486
Pancreatic Neoplasms
1470
Ovarian Neoplasms
1423
Leukemia
1389
Head and Neck Neoplasms
1284
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1282
Lymphoma, Non-Hodgkin
1231
Colonic Neoplasms
1159
Carcinoma, Hepatocellular
1142
Stomach Neoplasms
1127
Leukemia, Lymphocytic, Chronic, B-Cell
1090
Brain Neoplasms
1050
Rectal Neoplasms
980
Lymphoma, Follicular
979
Recurrence
975
Uterine Cervical Neoplasms
926
Glioblastoma
920
Carcinoma, Renal Cell
882
Lymphoma, Large B-Cell, Diffuse
853
Hodgkin Disease
777
Interventions
Octreotide
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Malignant Carcinoid Syndrome
×
Clear all
NCT00412061
2014-11-21
RADIANT-2
Novartis
Phase 3
Completed
429 enrolled
13 charts